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During the past decade, cancer drug development has shifted from a focus on cytotoxic chemo-
therapies to drugs that target specific molecular alterations in tumors. Although these drugs
dramatically shrink tumors, the responses are temporary. Research is now focused on overcoming
drug resistance, a frequent cause of treatment failure. Here we reflect on analogous challenges
faced by researchers in infectious diseases. We compare and contrast the resistance mechanisms
arising in cancer and infectious diseases and discuss how approaches for overcoming viral and
bacterial infections, such as HIV and tuberculosis, are instructive for developing a more rational
approach for cancer therapy. In particular, maximizing the effect of the initial treatment response,
which often requires synergistic combination therapy, is foremost among these approaches.
A remaining challenge in both fields is identifying drugs that eliminate drug-tolerant ‘‘persister’’ cells
(infectious disease) or tumor-initiating/stem cells (cancer) to prevent late relapse and shorten treat-
ment duration.The modern era of antimicrobial therapy is 60 years old. It has
produced agents that target bacterial cell wall biosynthesis (e.g.,
penicillins, cephalosporins, vancomycin, Isoniazid), protein
synthesis (e.g., aminoglycosides, tetracyclines, chloramphen-
icol, oxazolidinones, macrolides), RNA synthesis (e.g., rifampin),
and DNA metabolism (e.g., sulfonamides, quinolones). Despite
this diversity of targets, resistance remains a universal accompa-
niment to antimicrobial therapy. Microbes use remarkably
diverse strategies to overcome selective pressure, and much is
known about the mechanisms of antimicrobial resistance.
Although antimicrobial resistance remains a major problem on
a population level, the emergence of drug resistance in an indi-
vidual patient with a chronic infection can be prevented by the
administration of a highly effective combination therapy regimen,
which either cures the patient or prevents death from previously
lethal infections.
The history of targeted cancer therapy is much shorter than
that of infectious diseases, but already it is replete with a similarly
diverse range of resistance mechanisms. However, effective
combinations leading to cures have not yet emerged. Oncology
has a track record of prior success in developing curative combi-
nation chemotherapy for pediatric leukemia, germ cell tumors,
and lymphoma, but this progress required decades of empiri-
cally mixing and matching available agents. There is optimism
that this timeline can be shortened with targeted cancer drugs
because our understanding of cancer biology today is markedly
more advanced.
Here we compare and contrast examples of drug resistance in
infectious diseases and cancer, with the hope that lessonslearned in one field may inform the other. We acknowledge
that this is a forced comparison. There are fundamental differ-
ences in the principles underlying the search for drugs that target
a foreign invader (i.e., in infections) versus mutant cells that
emerge from the host (i.e., in cancer), particularly with regard
to anticipated toxicities. Yet, current drug-targeting strategies
in both fields share the goal of exploiting the unique dependen-
cies of each disease, such as tumor-specific mutations in
cancers or microbe/virus-specific targets in infectious agents.
Another challenge in comparing these disciplines are the
different definitions of treatment success. Resolution of the
illness in the patient is central to both, but the infectious diseases
field must also consider the impact of drug resistance on public
health. Overtreatment with broad spectrum antibiotics cures
most patients but hastens the emergence and spread of multi-
drug-resistant strains, which can impact the health of currently
uninfected individuals.
Rather than divide the discussion into separate sections on
infectious diseases and cancer, we consider both fields together,
beginning with mutational and nonmutational mechanisms of
resistance (Table 1). We follow with a review of successful
combination drug strategies in infectious diseases. We provide
insights into why they worked and highlight a few instances
when monotherapy is surprisingly effective in both disciplines.
We conclude with the argument that molecular diagnostics,
which already play a critical role in defining drug-sensitive
subsets of cancer patients, could also transform current infec-
tious diseases treatment. To learn more about the mechanistic
details of and treatment options for drug resistance in HIV,Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1089
Table 1. Mechanisms of Resistance
Mutational Nonmutational
mutation of drug target drug-tolerant persister cells
amplification of drug target tumor-initiating cells/cancer
stem cells
bypass of drug targeted pathway signaling pathway feedback
drug inactivation lineage switchingtuberculosis (TB), and malaria, see Review by Goldberg et al. on
page 1271 of this issue.
Mutational Mechanisms of Resistance
Mutation of the Drug Target
A common resistance mechanism shared across antimicrobial
and anticancer agents is mutation in the gene that encodes the
drug target (Figure 1A). HIV serves as an illustrative example of
this resistance mechanism. The goal of HIV therapy is long-
term suppression of viral replication with combinations of antire-
troviral agents targeting viral reverse transcriptase (RT),
protease, or integrase enzymes. Loss of viral suppression is
often associated with emergence of HIV-1 variants, which
express drug-resistant alleles of the viral RT, protease, or inte-
grase gene due to mutations (Blanco et al., 2011; Zolopa et al.,
1999). Mutations in drug targets are also common in antibacterial
resistance. For example, rifampicin binds and inhibits the
b subunit of the bacterial RNA polymerase enzyme complex
(Campbell et al., 2001). b subunit mutations that impair drug
binding confer rifampicin resistance. Resistance to b-lactam
antibiotics can also occur through drug target mutation. b-lac-
tam antibiotics, such as penicillins and cephalosporins, inhibit
bacterial peptidoglycan biosynthesis by binding and inhibiting
transpeptidases (i.e., penicillin-binding proteins or PBPs),
enzymes that crosslink the peptidoglycan peptide side chains.
PBP mutations that diminish the affinity for b-lactam confer
b-lactam resistance in a wide variety of gram-positive patho-
gens, including Staphylococcus aureus, Streptococcus pneu-
moniae, and Enterococcus (Zapun et al., 2008).
Drug target mutations are also common with many anticancer
agents, particularly in the growing class of kinase inhibitors that
target oncogenic driver mutations. This mechanism was first
demonstrated in patients with chronic myeloid leukemia (CML)
who developed resistance to the ABL kinase inhibitor imatinib.
Now this mechanism has been observed with nearly every
kinase inhibitor tested to date. In the case of CML, mutations
in the kinase domain of BCR-ABL impair imatinib binding,
although preserving the catalytic activity of the enzyme (ATP
hydrolysis) that is required for oncogenicity (Gorre et al., 2001).
Some mutations confer resistance by blocking interactions
between the drug and target through steric hindrance. Other
mutations restrict the flexibility of the enzyme to conformations
that are unsuitable for drug binding (Burgess et al., 2005; Gorre
et al., 2001; Shah et al., 2002). Similar mechanisms account for
resistance to epidermal growth factor receptor (EGFR) kinase
inhibitors and ALK kinase inhibitors in lung cancer, KIT kinase
inhibitors in gastrointestinal stromal tumors (GIST), platelet-
derived growth factor receptor (PDGFR) kinase inhibitors in
hypereosinohilic syndrome, and BRAF kinase inhibitors in mela-1090 Cell 148, March 16, 2012 ª2012 Elsevier Inc.noma (Antonescu et al., 2005; Choi et al., 2010; Cools et al.,
2003; Pao et al., 2005; Poulikakos et al., 2011). In CML and
lung cancer, drug-resistance mutations can be detected in
some patients prior to treatment with the kinase inhibitor and
can impact prognosis by shortening the time to disease progres-
sion. The drug-resistant allele is generally present in a small
minority of cells, but in a few cases, drug-resistant clones have
undergone substantial expansion in the absence of drug. This
observation raises the question of whether some resistance
mutations also confer a tumor fitness advantage (Shah et al.,
2002; Bean et al., 2007; Godin-Heymann et al., 2007; Mahes-
waran et al., 2008; Skaggs et al., 2006). This contrasts with HIV
infections, in which virions bearing drug-resistant RT mutations
generally have reduced viral fitness (Martinez-Picado and
Martı´nez, 2008).
Gene Amplification of the Drug Target or a Bypass
Pathway
Drug resistance can also occur through amplification of the drug
target gene in the absence of mutation (Figure 1B). A prime
example of this mechanism in cancer is the androgen receptor
(AR). The AR gene is amplified in 30% of prostate cancers
that have acquired resistance to standard androgen deprivation
therapy with drugs (e.g., leuprolide) that lower testosterone
production and AR antagonists (e.g., bicalutamide or flutamide)
that block ligand binding (Scher and Sawyers, 2005). BCR-ABL
gene amplification can also drive resistance to ABL kinase inhib-
itors in CML, although this mechanism is less common than
mutations in the kinase domain (Gorre et al., 2001). Amplification
of the dihydrofolate reductase (DHFR) gene confers resistance
to the chemotherapeutic agent methotrexate in cancer cell lines
(Schimke et al., 1978), but this mechanism has not emerged as
a common resistance mechanism in patients. However, amplifi-
cation of the bacterial DHFR gene can cause resistance to the
antibiotic trimethoprim (Steen and Sko¨ld, 1985).
Approximately 20% of patients with EGFRmutant lung cancer
develop resistance to EGFR inhibitors by amplification of
another receptor tyrosine kinase, MET (Engelman et al., 2007).
This mechanism has been termed ‘‘oncogene bypass’’ because
the primary drug target remains unaltered and continues to be in-
hibited by drug. Resistance occurs because MET activates
downstream components of the EGFR signaling pathway, by-
passing the need for EGFR (Figure 1B). A conceptually similar
mechanism has been documented with thymidine auxotrophs
of E. coli and Enterococcus. These strains can become resistant
to sulfonamides because the inhibition of thymidine biosynthesis
by the antibiotic can be bypassed by the acquisition of thymidine
from the environment (Maskell et al., 1978) (Figure 1B).
Drug Inactivation
The most common mechanism of antibacterial resistance is
drug destruction by bacterial enzymes (Figure 1C). b-lacta-
mases, which cleave the amide bond of the b-lactam ring, confer
resistance to the antibiotic through drug destruction. Progres-
sive chemical modification of the b-lactam nucleus to prevent
destruction by b-lactamases has yielded compounds that are
active against b-lactamase-producing organisms. However,
progressively broader spectrum b-lactamases, including some
capable of hydrolyzing all b-lactams and carbapenems, have
consequently become widespread. These broad spectrum
Figure 1. Mechanisms of Resistance to
Antimicrobials and Targeted Anticancer
Agents
(A) Resistance via target mutation. This mecha-
nism has been well described in both antimicrobial
resistance and tumor cell resistance. The red drug
binds tightly to its target (black square). A muta-
tional event leads to alteration in the binding site
for the drug (yellow circle), leading to loss of drug
binding. This mechanism governs resistance to
b-lactam antimicrobials (and other antimicrobial
classes) as well as resistance to kinase inhibitors.
(B) Resistance via bypass pathways. Treatment
with antimicrobial or anticancer agents (red lines)
leads to a block in the pathway converting X to Y.
Conceptually, Y can be a metabolite or a pheno-
typic state (e.g., cell proliferation). Resistance to
the effect of the drug can be mediated by upre-
gulation of a parallel pathway that allows Y to be restored. This mechanism of resistance has been documented in anticancer therapy, for example, amplification
of MET to bypass a drug-induced block in EGFR signaling.
(C) Resistance by drug destruction or modification. Bacterial enzymes, such as b-lactamases or aminoglycoside-modifying enzymes, mediate antimicrobial
resistance by drug destruction or modification. This mechanism has not been described for resistance to anticancer agents, although modification of anticancer
agents through CYPs can affect efficacy (although this effect is not mediated by the tumor cell).
(D) Intrinsic, nonmutational, resistance. Here the population of cells (either tumor or microbial) are genotypically identical. The red cells are drug sensitive and are
rapidly killed by antimicrobial or anticancer therapy, but the yellow cells are poorly killed by antimicrobial or cancer therapy (tolerant). These tolerant cells are
called microbial persisters or cancer stem cells. Therapy with antimicrobials or anticancer agents leads to substantial killing, but the persister cells are able to
resist treatment and can repopulate the infection or tumor with drug-sensitive cells, causing disease relapse.b-lactamases are an escalating concern and threaten the utility
of this class of antibiotics (Cornaglia et al., 2011).
Resistance through antibiotic modification is not limited to the
b-lactam class of antibiotics. Aminoglycoside antibiotics inhibit
protein synthesis by binding to the 30S subunit of the bacterial
ribosome. The most common mechanism of resistance to these
drugs is through bacterial acquisition of enzymes that covalently
modify the aminoglycoside by phosphorylation, acetylation, or
adenylation. The modified aminoglycoside no longer binds its
target on the ribosome.
In contrast to antibacterials, drug inactivation has not emerged
as amajor cause of resistance to anticancer agents. Cytochrome
P450 enzymes (CYPs) play a critical role in the metabolism of
many drugs through oxidation reactions that can inactivate the
compound or lead to its rapid elimination (Figure 1C). Although
this metabolic degradation was problematic for many classes
of drugs in the past, it is less relevant today because most
drug candidates are routinely counterscreened early in develop-
ment against panels of CYPs. Compounds that score as potent
CYP substrates are typically eliminated or chemically modified to
‘‘dial out’’ the CYP activity while preserving the desired anti-
cancer function.
Nonetheless, there are examples of drugs in which CYPmodi-
fication may affect therapeutic response. The antiestrogen
tamoxifen, which is widely used in the treatment of estrogen
receptor-positive breast cancer, is metabolized by CYP2D6 to
its primary active metabolite endoxifen. Some genetic variants
of CYP2D6 confer reduced levels of enzyme activity, and there
is evidence that women with these variants may not respond
as well to tamoxifen because they generate lower levels of en-
doxifen. Furthermore, CYP2D6 is inhibited by selective serotonin
reuptake inhibitors (SSRIs). SSRIs are commonly prescribed to
ameliorate ‘‘hot flashes,’’ but they may counteract the clinical
benefit of tamoxifen by blocking production of its primarymetab-
olite (Borges et al., 2006).Resistance to the antimycobacterial drugs isoniazid and
pyrazinamide, both important agents in the treatment of TB,
also occurs because of the failure to generate the active
metabolite of the drug. Both antibiotics are prodrugs that must
be activated by the TB bacterial enzymes KatG (for isoniazid)
and PncA (for pyrazinamide). Resistance to both drugs often
occurs through mutations in their respective activator enzymes
(Altamirano et al., 1994; Scorpio and Zhang, 1996; Zhang
et al., 1992).
Although conceptually similar, these mechanisms differ from
the example with tamoxifen/CYP2D6 because resistance to
isoniazid and pyrazinamide is cell autonomous. We are not
aware of examples of cancer drug inactivation mediated specif-
ically by tumor cells. This mechanism has not been considered
by most cancer scientists due to challenges in measuring
concentrations of the drug and potential metabolites in tumor
biopsies. However, advances in mass spectrometry technology
should enable suchmeasurements on amore routine basis. Drug
destruction should be evaluated as a potential cause of tumor-
mediated resistance in cases in which other mechanisms have
been excluded.
Nonmutational Resistance Mechanisms
Drug-Tolerant ‘‘Persister’’ Cells
In the earliest days of antimicrobials, it was observed that the
killing of a microbial population was rarely complete. A small
subpopulation of cells survived but did not have a drug-resis-
tance mutation. When expanded, these cells reverted to antimi-
crobial sensitivity (Figure 1D). This phenomenon, termed bacte-
rial persistence, is observed in a wide variety of bacterial taxa,
including M. tuberculosis, E. coli, and others (Connolly et al.,
2007; Lewis, 2010). It is widely suspected that persister cell pop-
ulations are responsible for the slow sterilization of many chronic
infections and consequent requirement for prolonged antibi-
otic therapy. There is great interest in identifying molecularCell 148, March 16, 2012 ª2012 Elsevier Inc. 1091
determinants of persistence because knowledge of such path-
ways could lead to more effective antimicrobials that quickly
eliminate this reservoir of cells. Such drugs could reduce the
chance of late relapse and shorten duration of treatment. In the
case of TB, a curative regimen administered over several weeks
rather than 6–9 months could have profound consequences on
treatment compliance, with obvious public health implications.
We currently have little insight into the molecular basis of
persistence. Recent evidence suggests that toxin-antitoxin (TA)
modules may be molecular determinants of persistence in
some bacteria, presumably by the induction of growth arrest in
a subpopulation of cells through toxin-mediatedmRNA cleavage
(Maisonneuve et al., 2011; Moyed and Bertrand, 1983; Wolfson
et al., 1990). But, many questions remain, including the exact
mechanisms of TA-mediated persistence, the generalizability
of this mechanism to chronic infections, and the therapeutic
benefit of targeting TA modules. Similarly, recent evidence
from the M. marinum system suggests that M. tuberculosis
drug tolerance in vivo may be mediated by host-inducible drug
efflux pumps (Adams et al., 2011). Although the exact contribu-
tion of drug efflux to drug tolerance in vivo remains to be deter-
mined, these findings suggest a druggable target that would
increase antimicrobial killing by presently available antimyco-
bacterials.
Tumor-Initiating/Cancer Stem Cells
The phenomenon of bacterial persistence shares conceptual
similarities with evidence that late relapses of some cancers
may be due to tumor-initiating or cancer stem cells that are not
eliminated by most treatments (Figure 1D). The existence of
cancer stem cells is a topic of considerable controversy (Rossi
et al., 2008), but this is not germane to our discussion here.
What is relevant is the observation that, even following effective
treatment regimens, residual cancer cells persist and are
responsible for late relapse. Acute myeloid leukemia (AML)
serves as an illustrative example, in which initial treatment with
induction chemotherapy is quite effective in inducing remission,
but relapse is inevitable unless additional rounds of consolida-
tion chemotherapy are administered.
Several preclinical studies have documented that these
residual cells do not have mutations in the drug target or other
factors that could explain resistance. Like residual persister cells
after antibiotic treatment, these residual cancer cells, when
expanded in the absence of drug, give rise to drug-sensitive
populations of cancer cells (Sharma et al., 2010). These cancer
persister cells tend to express cell-surface antigens typically
present on tissue stem cells, raising the possibility that stem cells
are inherently drug resistant.
One potential explanation for their resistance is expression of
drug efflux pump proteins, such as MDR (multidrug resistance),
which are naturally expressed at higher levels in stem cells.
However, cancer cells can persist following treatment with drugs
that are not MDR substrates. Another potential mechanism is
survival signaling mediated through growth factors expressed
by adjacent cells in the tumor microenvironment or metastatic
niche (Guise, 2010). For example, the CXCR4 receptor plays
a critical role in anchoring hematopoietic stem cells (HSCs)
and CXCR4-positive AML cells to niches in the bone marrow
microenvironment through interaction with the stromal factor1092 Cell 148, March 16, 2012 ª2012 Elsevier Inc.SDF-1. CXCR4 inhibitors mobilize HSCs into circulation
(DiPersio et al., 2009) and enhance the efficacy and duration of
response to induction chemotherapy (Nervi et al., 2009). Similar
to antibacterial persister drugs, compounds that selectively elim-
inate tumor-initiating cells could complement existing cancer
therapies (Gupta et al., 2009; Reya et al., 2001).
Feedback due to Signaling Pathway Inhibition
When cancer cells are exposed to drugs that block signaling
pathways, such as kinase inhibitors, many tumor cells compen-
sate by activating other signaling pathways. The mechanism of
these feedback responses is complex and related to concepts
of network robustness and redundancy that have emerged
from systems biology research (Lander, 2011). In the context
of cancer, inhibition of one signaling pathway initiates compen-
satory feedback responses that can lead to the activation of
another (Carver et al., 2011; Chandarlapaty et al., 2011; O’Reilly
et al., 2006; Pratilas et al., 2009). These observations predict that
monotherapy with some inhibitors, particularly those targeting
the PI3K signaling pathway, is unlikely to be effective unless
paired with inhibitors of the compensatory pathway. Interest-
ingly, there is currently no evidence for feedback as amechanism
of resistance to anti-infectious agents, likely because these
drugs tend to target essential steps in the replication of the
organism (e.g., cell wall synthesis, viral replication, etc.) rather
than signaling pathways. However, similar mechanisms of resis-
tance may arise with antimicrobials that target virulence path-
ways that are not essential to cell viability (Clatworthy et al.,
2007).
Lineage Switching
Studies of acquired resistance to EGFR inhibitors in lung cancer
reveal that recurrent tumors in some patients undergo a lineage
switch from non-small cell to small cell carcinoma (Sequist et al.,
2011). Clonality studies document that both tumors arose from
a common EGFR mutant tumor rather than from two indepen-
dent cancers, indicating that the tumor has shifted to a different
cellular differentiation pathway. Switching to the small cell
lineage (by an unknown mechanism that presumably involves
cellular reprogramming) relieves cells of their dependence on
EGFR, which was critical for survival of the non-small cell tumor
lineage. A somewhat analogous phenomenon has been
observed with antibiotics, in which resistance to drugs targeting
the bacterial cell wall can occur through the cell wall-deficient
bacteria, called L-forms (Allan et al., 2009).
Overcoming Resistance
Although our knowledge is still incomplete, progress in decipher-
ing mechanisms of resistance to targeted cancer therapy is
already guiding solutions to overcome it. The recognition that
point mutations in the BCR-ABL kinase domain confer resis-
tance to the first-generation inhibitor for the ABL kinase inhibitor
imatinib led rapidly to efforts to find other ABL inhibitors effective
against the mutant BCR-ABL alleles. Within 5 years, two next-
generation ABL inhibitors, dasatinib and nilotinib, were approved
for the treatment of imatinib-resistant CML (Kantarjian et al.,
2007; Talpaz et al., 2006). Dasatinib is notable because its
activity against imatinib-resistant BCR-ABLmutants is explained
by its ability to bind multiple distinct conformations of BCR-ABL,
thereby restricting the potential for escape mutants (Burgess
Figure 2. Relative Efficacy of Mono- versus Combination Therapy
for Three Chronic Infections and Effect on Resistance
(A) The three curves schematically indicate the reduction in viral burden during
monotherapy of HIV (dashed green line), combination therapy for HIV (solid
green line), and monotherapy for hepatitis B (solid red line). Monotherapy of
HIV produces a transient reduction in viral load, which becomesmore dramatic
and sustained with combination therapy. In contrast, monotherapy for hepa-
titis B (with entecavir or tenofovir) produces sustained virologic suppression.
See text for specific references.
(B) Monotherapy and combination therapy for tuberculosis. The y axis sche-
matically represents clinical response (reduction in bacterial load, clinical
improvement, radiographic improvement). Monotherapy and combination
therapy have similar efficacy early in treatment, but the benefit of monotherapy
is not sustained.
(C) Effect of combination therapy on emergence of resistance. The y axis
represents the % of patients with resistant bacteria or viruses according to
week of treatment. HIV and TB resistance emerges rapidly during mono-
therapy, leading to the loss of therapeutic effect depicted in panel A (HIV) and
panel B (TB). Combination therapy for HIV and TB suppresses the emergence
of resistant organisms and allows the sustained therapeutic benefit depicted in
(A) and (B). In contrast, monotherapy for hepatitis B with entecavir or tenofovir
is not associated with the emergence of resistant viruses, allowing sustained
therapeutic benefit with monotherapy.et al., 2005; Shah et al., 2002). A second example has emerged
from the discovery that prostate cancers resistant to standard
androgen deprivation therapy remain dependent on AR signaling
(Chen et al., 2004). Two new drugs, abiraterone and MDV3100,
impair AR signaling in this drug-resistant setting and are effective
in men with metastatic prostate cancer resistant to standard
hormone and chemotherapy (de Bono et al., 2011; Scher et al.,
2010; Tran et al., 2009).
These examples underscore the importance of understanding
resistancemechanisms and the rapid progress that can bemade
by leveraging these insights. But they also represent partial solu-
tions because sequential treatment with these different targeted
agents is not curative. This current scenario in cancer contrasts
strikingly with the current treatment of two previously lethal
infections, TB and HIV: combinations of antibiotics cure TB,
whereas combinations of antivirals can indefinitely suppress
the HIV virus. Physicians treating these diseases in the past
faced a situation remarkably similar to that faced by oncologists
today. Successful combination regimens arose only after
attempts to treat these infections with monotherapy failed.
HIV: Importance of Maximal Suppression of Viral Load at
Treatment Initiation
HIV cannot be cured with current antiretroviral therapy, but
mortality is dramatically reduced through combination antiretro-
viral drug therapy. The first major success in HIV therapy came
from nucleoside analogs, such as zidovudine (AZT). These
analogs inhibit viral replication by causing chain termination
when RT incorporates the analogs into the viral cDNA. Although
testing of serum viral loads was not available at that time, the
clinical benefit of AZT was evident after 12 weeks in patients
with AIDS. However, the efficacy of the therapy was short lived:
CD4 T cell counts returned to the levels of placebo-treated
patients in 24 weeks, indicating a significant but transient clinical
benefit (Fischl et al., 1987). Similar results were observed with
the nucleoside RT inhibitor lamivudine (3TC): nearly 100% of
patients had lamivudine resistance by week 12 of monotherapy
(Schuurman et al., 1995). Monotherapy with the protease inhib-
itor saquinavir also revealed substantial short-term clinical
benefit, which was lost over the course of the 24 week observa-
tion period (Schapiro et al., 1996). This failure of HIV antiviral
monotherapy is schematically depicted in Figure 2A.
In all of these examples (and other attempts of monotherapy),
the cause of clinical failurewas the emergence of virionswithmu-
tations that confer resistance to the administered agent (Richman
et al., 1994; Schuurman et al., 1995; Zolopa et al., 1999)
(Figure 2C). The biologic basis for this rapid emergence of resis-
tance is the massive pool of HIV virions in an infected host, esti-
mated to be 1010 new virions per day (Perelson et al., 1996).
This pool generates a large number of possible mutant virions,
which have a selective growth advantage during monotherapy.
These results rapidly led to the testing of combination regi-
mens, first with dual-nucleoside analogs (Eron et al., 1995) and
then with triple-drug regimens, including two nucleosides and
a protease inhibitor, such as saquinavir or indinavir. Trials
comparing AZT/3TC and AZT/3TC/indinavir revealed that the
three-drug combination suppressed HIV-1 viral load more
potently than the two-drug combination and substantially low-
ered the number of HIV-related deaths (Gulick et al., 1997;Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1093
Hammer et al., 1997). These results have been replicated
multiple times with multiple different combination therapy regi-
mens and have led to a highly evolved standard of care for
HIV, infection consisting of three-drug combination therapy
now known as HAART (highly active antiretroviral therapy). The
key to this success is the more rapid and sustained decline in
HIV burden achieved through HAART, thereby preventing the
emergence of resistant virions (Figures 2A and 2C).
TB: Importance of Preventing Outgrowth of Drug-
Resistant Subclones
TB is remarkable for its insidious onset and slow progression,
which, in the preantibiotic era, was usually fatal. The first anti-
TB drugs were paraminosalicylic acid (PAS) and streptomycin.
Both drugs were initially used as monotherapy with significant
clinical improvement over 1–2 months of therapy. This success
was quickly followed by loss of clinical efficacy due to the emer-
gence of streptomycin- or PAS-resistant TB strains (British
Medical Research Council, 1947, 1948, 1950; Lehmann, 1946).
Next, a series of trials were performed comparing streptomycin
and PAS monotherapy to streptomycin plus PAS combination
therapy. Ultimately, the combination therapy proved superior
over monotherapy. All three treatment strategies showed similar
improvement at 6 months in terms of the resolution of fever,
radiographic improvement, and weight gain, but the combina-
tion therapy was ultimately superior because it prevented the
emergence of streptomycin resistance (Figures 2B and 2C)
(British Medical Research Council, 1950).
Similar results emerged from trials with the current standard-
of-care drug isoniazid (INH). INH monotherapy was initially as
effective as streptomycin/PAS combination therapy but ulti-
mately failed due to the emergence of INH-resistant strains
(British Medical Research Council, 1950, 1952). These insights
led to the current, curative three- to four-drug, 6–12 month regi-
mens that are now the standard of care (Fox et al., 1999). The key
concept underlying the success of antimicrobial TB therapy is
that combination therapy is necessary to prevent the emergence
of resistance. In contrast, the success of HIV combination
therapy is partially based on a more rapid, synergistic suppres-
sion of the infectious agent and partially due to the suppression
of resistance (Figure 2).
Exceptions: Examples of Successful Monotherapy
Acute Bacterial Infections
Antibiotic monotherapy for most acute bacterial infections is
curative in the absence of pre-existing antimicrobial resistance.
Despite substantial evidence for synergistic killing by antibiotic
combinations in vitro, definitive evidence supporting the clinical
benefit of combination therapy for acute-onset infections, such
as bacterial pneumonia or urinary tract infection, is generally
lacking (Del Favero et al., 2001). It is not known why antibiotic
monotherapy is so effective for most acute infections, but we
speculate that the magnitude and kinetics of decline in bacterial
burden are sufficiently steep to prevent the emergence of resis-
tance and therefore obviate the need for combination therapy. In
contrast, more slowly progressive bacterial infections, such as
enterococcal endocarditis, require multiple antibiotics for elimi-
nation. It is also likely that the host immune system plays a role
in eliminating minimal residual disease because patients with1094 Cell 148, March 16, 2012 ª2012 Elsevier Inc.reduced neutrophil counts (e.g., from chemotherapy treatment)
often require more prolonged antibiotic therapy and generally
recover quickly once the neutropenia resolves.
Hepatitis B
Hepatitis B is a chronic viral infection of hepatocytes that even-
tually can lead to cirrhosis and hepatocellular carcinoma. Nucle-
oside analogs, such as entecavir, lamivudine, and tenofovir (the
latter two are also used as antiretroviral therapy for HIV), have
similar activities against the hepatitis B DNA virus due to the
RT activity of the viral polymerase (which copies the pregenomic
RNA into DNA). Monotherapy with each of these drugs
suppresses viral burden substantially but, surprisingly, is not
accompanied by rapid emergence of drug-resistant hepatitis B
virions. The incidence of lamivudine-resistant hepatitis B is
20% after 1 year of therapy, and almost no resistance is
observed with the newer agents tenofovir or entecavir, with 1
and 5 years of follow up, respectively (Chang et al., 2006; Lok
andMcMahon, 2009; Marcellin et al., 2008). Notably, the decline
in viral burden with hepatitis B monotherapy occurs over
months, at a pace comparable to monotherapy for HIV or TB
(Figure 2A), indicating that the clinical efficacy of hepatitis B
monotherapy is based on the fact that drug-resistant virions
rarely emerge. The biologic basis for this serendipitous lack of
resistance in hepatitis B is unknown because the same drugs tar-
geting a similar enzyme (i.e., RT) rapidly generate resistant HIV
when used as monotherapy (Figure 2C).
Chronic Myeloid Leukemia
As discussed earlier, resistance tomonotherapy with ABL kinase
inhibitors occurs, but the relapse rate is quite low (4%–5% in
the first year) if treatment is initiated in early chronic phase. By
comparison, more than half of patients with most other types
of tumors (e.g., lung cancer and melanoma) treated with kinase
inhibitors relapse after 1 year. Longer follow up of CML patients
receiving imatinib monotherapy has shown that the risk of
relapse declines after 5 years and may plateau (Hochhaus
et al., 2009), suggesting that many patients with CML can be
successfully managed indefinitely with monotherapy. The rate
of decline in CML disease burden over the initial 3–6 months of
treatment, as measured by PCR for BCR-ABL mRNA transcripts
in the blood, is a critical determinant of the durability of response.
Specifically, CML patients who obtain a three log reduction in
tumor burden on imatinib have a low risk of subsequent relapse
(Hughes et al., 2010). Early data with the second-generation
inhibitors dasatinib and nilotinib indicate that an even greater
proportion of CML patients reach this endpoint (Kantarjian
et al., 2010; Saglio et al., 2010). Similar to the importance of
achieving a rapid and substantial decline in viral load with HIV
therapy, the success of CML monotherapy is most likely due to
the dramatic reduction in tumor burden. Extrapolating to lung
cancer and melanoma, it may be possible to achieve similar
long-term success if we focus our efforts on obtaining deeper
reductions in tumor burden using more potent agents and rele-
vant combinations.
Precision Diagnostics: Essential for Targeted Cancer
Drugs, Missed Opportunity for Antibacterials
The advent of targeted cancer therapies that are active against
a subset of tumors with specific mutations mandated the parallel
development of diagnostic tests that can determine the pres-
ence of these mutations in clinically relevant timeframes. Exam-
ples include the assessment of Her2/Neu gene amplification in
breast cancer to identify women who would benefit from trastu-
zumab; EGFR mutation in lung cancer for sensitivity to erlotinib
or gefitinib; BRAF mutation in melanoma for response to vemur-
afenib (PLX4720); and others. This priority represents a move
away from broadly targeted cytotoxic therapies in which
tumor/patient-specific molecular diagnostics have not been
used to make treatment decisions.
A similar logic could easily guide precision diagnostics of sus-
pected infections to determine the presence of a specific path-
ogen, rapidly define its drug susceptibility profile, and guide
therapy. Examples of this strategy that have gained some trac-
tion are (1) CCR5 tropic HIV and the use of maraviroc, a CCR5
antagonist entry inhibitor (Gulick et al., 2008); (2) PCR-based
determination of rifampin resistance in TB (Boehme et al.,
2010); and (3) HIV genotypic resistance testing, in which the
susceptibility of a patient’s HIV virus can be predicted based
on protease, RT, or integrase mutations present.
Despite these advances, similar diagnostics are either not
available or not in widespread use for the most common infec-
tious diseases, largely because of the false comfort in giving
broad-spectrum antimicrobials that are relatively nontoxic and
safe for any individual patient (Casadevall, 2009). This has led
to complacency and blunted the push for specific diagnostics
that would allow (1) administration of narrow-spectrum antimi-
crobials; (2) early recognition of antibiotic resistance; and (iii)
differentiation of infections from noninfectious (or viral) diseases
with similar clinical presentations. Consequently, we have a situ-
ation of antibiotic overuse, which compromises public health by
selection for drug-resistant organisms (particularly in hospitals),
increases the frequency of life-threatening side effects, such as
antibiotic-associated colitis, and results in inefficient and costly
heath care expenditures. We note that the problem of resistance
as a public health hazard is unique to infectious diseases
because the resistant organism is transmissible, and therefore,
resistance in one patient can affect the population as a whole.
In contrast, although tumor cell resistance is detrimental to the
individual patient, it does not harm others who may be afflicted
with the same cancer.
Conclusions and Challenges
Except in rare examples, such as CML, there is little doubt that
combination therapy will be required for sustained clinical
benefit of targeted agents against cancer. The experience with
infectious diseases highlights the importance of combinations
that achieve rapid, efficient cancer suppression (as in HIV) and
prevent the emergence of resistance (as in HIV and TB). Current
paradigms of oncology drug development are not aligned in
ways that allow these goals to be pursued efficiently. Instead,
business and regulatory incentives drive commercial drug devel-
opers to seek approval for monotherapy indications before em-
barking on combination studies. Based on the short duration of
response tomany recently approved anticancer agents, coupled
with the precedent of failed monotherapy in chronic infectious
diseases, one might ask whether the obligatory phase of mono-
therapy approval should be bypassed. The FDA recently draftednew guidelines for developing two or more investigational drugs
in combination to encourage drug makers to adopt a combina-
tion rather than monotherapy strategy for registration (FDA,
2010), but it is too early to assess the impact of these changes.
Our perspective as academic physician-scientists with experi-
ence in drug development is that additional measures are
required to incentivize commercial sponsors to move to combi-
nation therapy trials early in drug development. One powerful
motivation might be patent life extension, as has been success-
fully implemented for pediatric indications, particularly when the
combination requires collaboration between two different drug
makers. Activism on the part of physicians and patients may
also be essential. Clinical investigators might collectively
‘‘demand’’ early combination studies from sponsors by refusing
to conduct single-agent studies until firm commitments to
combination trials are in place. Each of these strategies requires
extreme coordination of goals among relevant stakeholders.
Early efforts in the TB community to streamline the path of new
drugs into combination TB regimens could provide a template
for similar efforts in anticancer therapy (Critical Path Institute,
2010).
Another variable that could delay development of combination
cancer therapy regimens is the paucity of data on coadministra-
tion of two or more targeted agents. In contrast to infectious
diseases, in which most drugs are specific for the pathogen, tar-
geted cancer agents typically impact normal and tumor cells,
which could lead to unacceptable side effects. The fact that
most targeted cancer therapies have highly favorable toxicity
profiles relative to cytotoxic chemotherapy is cause for opti-
mism. However, the current focus on monotherapy could
complicate the investigation of tolerable combinations because
dose and schedule are selected exclusively based on tolerability
of monotherapy. Combination studies of targeted therapies typi-
cally begin by evaluating tolerability of each monotherapy
regimen given simultaneously. If additive toxicities are observed
(as might be expected), the combination might be abandoned
prematurely. If early development decisions were, instead,
driven by strategies that plan for combination therapy rather
than monotherapy, clinical safety and efficacy could be as-
sessed more quickly.
Another challenge is the need for better technologies to quan-
tify disease burden over a wide range, as is possible for viral load
assessment in HIV and hepatitis B. The rapid approval of ABL
kinase inhibitors in CML was enabled, in part, by the availability
of highly sensitive and quantitative assays of tumor burden (cyto-
genetics, PCR) that detect disease well below the threshold of
traditional clinical response. Similar assays for solid tumors do
not exist today, but proof of concept for quantitative assessment
of circulating tumor DNA levels in blood has been established for
several types of tumors (Leary et al., 2010). Once in place, these
assays might also serve as early endpoints for drug approval, as
they did for HIV, hepatitis B, and CML.
Curative regimens must also overcome the problem of
subclinical reservoirs of persistent disease. Experimental strate-
gies to define the molecular basis for persistence of cancer cells
or microbes deserve more focused attention because the
insights gained have the potential to eliminate drug-tolerant cells
and thereby avoid prolonged treatment regimens, which areCell 148, March 16, 2012 ª2012 Elsevier Inc. 1095
inevitably compromised by chronic toxicity and noncompliance.
Recent data in cancer suggest that the immune system could be
harnessed to eliminate minimal residual disease. Stimulation of
host T lymphocytes by the anti-CTLA4 antibody ipilimumab
induces tumor regression and prolongs survival in patients with
metastatic melanoma (Robert et al., 2011). Remarkably, some
patients remain in remission for years after therapy ceases and
may be cured. This long-term success could be explained by
the elimination of drug-tolerant persister cells by immune
effector cells or by ongoing antitumor immunity that prevents
expansion of tumor cells that persist indefinitely. There is clinical
precedent for both of thesemechanisms from allogeneic marrow
transplantation data in CML in which depletion or infusion of
donor T lymphocytes can profoundly impact treatment response
(Mackinnon, 1997).
Finally, with more and more evidence supporting the potential
value of genome-based medicine, the escalating problem of
antimicrobial resistance should motivate the infectious diseases
community to strive for more precise diagnostics that would
allow more specific or limited use of antimicrobial agents. The
advent of these technologies in targeted cancer therapy
provides a template that the infectious diseases community
should leverage.
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